Clinical evidence suggests that the use of PARP inhibitors is not restricted to BRCA1 or BRCA2 mutated cancers, but that it also targets non-BRCA mutated ovarian cancer [16] and can be useful in combination therapy. This evidence concerns the gene BRCA2 and ovarian cancer.